Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954964749> ?p ?o ?g. }
- W2954964749 endingPage "977" @default.
- W2954964749 startingPage "977" @default.
- W2954964749 abstract "The determination of optical coherence tomography (OCT) central subfield thickness (CST) is an objective measure, and visual acuity (VA) is a subjective measure. Therefore, using OCT CST changes as a surrogate for VA changes in diabetic macular edema seems reasonable. However, studies suggest that change in OCT CST following anti-vascular endothelial growth factor (anti-VEGF) treatment for diabetic macular edema is correlated with changes in VA but varies substantially among individuals, and so may not be a good surrogate for changes in VA.To determine associations between changes in VA and changes in OCT CST across 3 anti-VEGF agents (aflibercept, bevacizumab, or ranibizumab) used in a randomized clinical trial for diabetic macular edema.Post hoc analyses were conducted of DRCR Retina Network Protocol T among 652 of 660 participants (98.8%) meeting inclusion criteria for this investigation. The study was conducted between August 22, 2012, and September 23, 2015. The post hoc data collection and analysis were performed from May 29 to July 11, 2018.Six monthly intravitreous anti-VEGF injections (unless success was achieved after 3-5 months) were administered; subsequent injections or focal/grid laser photocoagulation treatments were given as needed per protocol to achieve stability.Association between changes in VA letter score with changes in CST at 12, 52, and 104 weeks after randomization to aflibercept, bevacizumab, or ranibizumab.Of the 652 participants, 304 were women (46.6%); median age was 61 years (interquartile range, 54-67 years). The correlation between CST and VA at the follow-up visits was 0.24 (95% CI, 0.16-0.31) in 616 patients at 12 weeks, 0.31 (95% CI, 0.24-0.38) in 609 patients at 52 weeks, and 0.23 (95% CI, 0.15-0.31) in 566 patients at 104 weeks. The correlation coefficients of change in VA vs change in OCT CST for these time intervals were 0.36 (95% CI, 0.29-0.43) at 12 weeks, 0.36 (95% CI, 0.29-0.43) at 52 weeks, and 0.33 (95% CI, 0.26-0.41) at 104 weeks.Changes in CST appear to account for only a small proportion of the total variation in changes in VA. These findings do not support using changes in OCT CST as a surrogate for changes in VA in phase 3 clinical trials evaluating anti-VEGF for diabetic macular edema or as a guide to inform the physician or patient about changes in VA after anti-VEGF treatment.ClinicalTrials.gov identifier: NCT01627249." @default.
- W2954964749 created "2019-07-12" @default.
- W2954964749 creator A5008816970 @default.
- W2954964749 creator A5011697010 @default.
- W2954964749 creator A5029924808 @default.
- W2954964749 creator A5030881763 @default.
- W2954964749 creator A5039879095 @default.
- W2954964749 creator A5059376308 @default.
- W2954964749 creator A5061503632 @default.
- W2954964749 creator A5091082221 @default.
- W2954964749 creator A5091736159 @default.
- W2954964749 date "2019-09-01" @default.
- W2954964749 modified "2023-10-17" @default.
- W2954964749 title "Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab" @default.
- W2954964749 cites W1574902248 @default.
- W2954964749 cites W1652166925 @default.
- W2954964749 cites W1786299986 @default.
- W2954964749 cites W2022886290 @default.
- W2954964749 cites W2034306361 @default.
- W2954964749 cites W2037557484 @default.
- W2954964749 cites W2095260304 @default.
- W2954964749 cites W2510096069 @default.
- W2954964749 cites W2616361514 @default.
- W2954964749 cites W2737035471 @default.
- W2954964749 cites W2789784671 @default.
- W2954964749 cites W2886062143 @default.
- W2954964749 cites W2891994468 @default.
- W2954964749 cites W4292528167 @default.
- W2954964749 cites W922383587 @default.
- W2954964749 doi "https://doi.org/10.1001/jamaophthalmol.2019.1963" @default.
- W2954964749 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6604439" @default.
- W2954964749 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31246237" @default.
- W2954964749 hasPublicationYear "2019" @default.
- W2954964749 type Work @default.
- W2954964749 sameAs 2954964749 @default.
- W2954964749 citedByCount "80" @default.
- W2954964749 countsByYear W29549647492019 @default.
- W2954964749 countsByYear W29549647492020 @default.
- W2954964749 countsByYear W29549647492021 @default.
- W2954964749 countsByYear W29549647492022 @default.
- W2954964749 countsByYear W29549647492023 @default.
- W2954964749 crossrefType "journal-article" @default.
- W2954964749 hasAuthorship W2954964749A5008816970 @default.
- W2954964749 hasAuthorship W2954964749A5011697010 @default.
- W2954964749 hasAuthorship W2954964749A5029924808 @default.
- W2954964749 hasAuthorship W2954964749A5030881763 @default.
- W2954964749 hasAuthorship W2954964749A5039879095 @default.
- W2954964749 hasAuthorship W2954964749A5059376308 @default.
- W2954964749 hasAuthorship W2954964749A5061503632 @default.
- W2954964749 hasAuthorship W2954964749A5091082221 @default.
- W2954964749 hasAuthorship W2954964749A5091736159 @default.
- W2954964749 hasBestOaLocation W29549647491 @default.
- W2954964749 hasConcept C118487528 @default.
- W2954964749 hasConcept C119060515 @default.
- W2954964749 hasConcept C126322002 @default.
- W2954964749 hasConcept C134018914 @default.
- W2954964749 hasConcept C141071460 @default.
- W2954964749 hasConcept C168563851 @default.
- W2954964749 hasConcept C204243189 @default.
- W2954964749 hasConcept C2776694085 @default.
- W2954964749 hasConcept C2777802072 @default.
- W2954964749 hasConcept C2778257484 @default.
- W2954964749 hasConcept C2778749236 @default.
- W2954964749 hasConcept C2779829184 @default.
- W2954964749 hasConcept C2780347916 @default.
- W2954964749 hasConcept C2781100027 @default.
- W2954964749 hasConcept C555293320 @default.
- W2954964749 hasConcept C67761136 @default.
- W2954964749 hasConcept C71924100 @default.
- W2954964749 hasConceptScore W2954964749C118487528 @default.
- W2954964749 hasConceptScore W2954964749C119060515 @default.
- W2954964749 hasConceptScore W2954964749C126322002 @default.
- W2954964749 hasConceptScore W2954964749C134018914 @default.
- W2954964749 hasConceptScore W2954964749C141071460 @default.
- W2954964749 hasConceptScore W2954964749C168563851 @default.
- W2954964749 hasConceptScore W2954964749C204243189 @default.
- W2954964749 hasConceptScore W2954964749C2776694085 @default.
- W2954964749 hasConceptScore W2954964749C2777802072 @default.
- W2954964749 hasConceptScore W2954964749C2778257484 @default.
- W2954964749 hasConceptScore W2954964749C2778749236 @default.
- W2954964749 hasConceptScore W2954964749C2779829184 @default.
- W2954964749 hasConceptScore W2954964749C2780347916 @default.
- W2954964749 hasConceptScore W2954964749C2781100027 @default.
- W2954964749 hasConceptScore W2954964749C555293320 @default.
- W2954964749 hasConceptScore W2954964749C67761136 @default.
- W2954964749 hasConceptScore W2954964749C71924100 @default.
- W2954964749 hasIssue "9" @default.
- W2954964749 hasLocation W29549647491 @default.
- W2954964749 hasLocation W29549647492 @default.
- W2954964749 hasLocation W29549647493 @default.
- W2954964749 hasLocation W29549647494 @default.
- W2954964749 hasOpenAccess W2954964749 @default.
- W2954964749 hasPrimaryLocation W29549647491 @default.
- W2954964749 hasRelatedWork W2176136391 @default.
- W2954964749 hasRelatedWork W2551646801 @default.
- W2954964749 hasRelatedWork W2562678857 @default.
- W2954964749 hasRelatedWork W2766804807 @default.
- W2954964749 hasRelatedWork W2790038519 @default.